Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Breast Cancer

Search In Journal Title:

Abbravation: Breast Cancer

Search In Journal Abbravation:

Publisher

Springer Japan

Search In Publisher:

DOI

10.1007/bf02796582

Search In DOI:

ISSN

1880-4233

Search In ISSN:
Search In Title Of Papers:

Topoisomerase II alpha expression and the Ki67 la

Authors: Hideaki Tokiniwa Jun Horiguchi Daisuke Takata Mami Kikuchi Nana Rokutanda Rin Nagaoka Ayako Sato Hiroki Odawara Katsunori Tozuka Tetsunari Oyama Izumi Takeyoshi
Publish Date: 2011/07/02
Volume: 19, Issue: 4, Pages: 309-314
PDF Link

Abstract

Topoisomerase II alpha Topo IIa is involved in DNA replication and is a molecular target for anthracyclinebased chemotherapy The Ki67 labeling index LI is an evaluation of tumor cell proliferation The objective of this study was to evaluate relationships among Topo IIa expression the Ki67 LI and prognostic factors in estrogen receptor ERpositive human epidermal growth factor type2 HER2negative breast cancerSeventyone patients were diagnosed with ERpositive HER2negative breast cancer between July 2003 and December 2004 Formalinfixed paraffinembedded tumor specimens were stained for Topo IIa expression and Ki67 LI We investigated the correlation of the level of Topo IIa expression and the Ki67 LI with clinical factors such as age tumor size progesterone receptor status nodal status nuclear grade and lymphovascular invasion LVIStatistically significant differences were observed between Topo IIa overexpression nuclear grade p = 0036 and LVI p = 0029 Topo IIa overexpression was statistically correlated with the Ki67 LI p  00001 A statistically significant difference was observed between the Ki67 LI and nuclear grade p = 001 Survival analysis revealed the significant prognostic value of Ki67 LI in patients with ERpositive HER2negative breast cancer p = 0003Ki67 LI is a strong prognostic factor in ERpositive HER2negative breast cancer Topo IIa overexpression was significantly correlated with the Ki67 LI nuclear grade and LVI These findings suggest use of Topo IIa expression as a proliferation marker and a prognostic factor in ERpositive HER2negative breast cancer

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma
  2. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage
  3. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort
  4. Suspicious calcifications in benign breast lesions: a radio-pathologic correlation
  5. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast
  6. Feature extraction via composite scoring and voting in breast cancer
  7. Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution
  8. Biopsy sampling of breast lesions: comparison of core needle- and vacuum-assisted breast biopsies
  9. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha
  10. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
  11. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer
  12. Diagnosis and management of primary breast sarcoma
  13. Recurrent read-through fusion transcripts in breast cancer
  14. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
  15. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells
  16. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis
  17. The impact of oophorectomy on survival after breast cancer in BRCA1 -positive breast cancer patients
  18. Impact of carpal tunnel syndrome surgery on women with breast cancer-related lymphedema
  19. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
  20. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
  21. Body weight and risk of breast cancer in BRCA1/2 mutation carriers
  22. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
  23. Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?
  24. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial
  25. CYP1B1 and predisposition to breast cancer in Poland
  26. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
  27. Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods
  28. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
  29. The effect of delays in treatment for breast cancer metastasis on survival
  30. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
  31. Transactivation of ERα by Rosiglitazone induces proliferation in breast cancer cells
  32. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk
  33. Epigenetic Therapy in Breast Cancer
  34. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
  35. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis
  36. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
  37. Metformin and breast cancer risk: a meta-analysis and critical literature review
  38. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy
  39. XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects
  40. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
  41. Association of progesterone receptor gene ( PGR ) variants and breast cancer risk in African American women
  42. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
  43. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
  44. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature
  45. Postmenopausal estrogen monotherapy–associated breast cancer risk is modified by CYP17A1 _-34_T>C polymorphism
  46. Women’s features and inter-/intra-rater agreement on mammographic density assessment in full-field digital mammograms (DDM-SPAIN)
  47. Promoter methylation reduces C/EBP δ (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors
  48. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
  49. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
  50. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
  51. Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975–2001
  52. PET/CT supports breast cancer diagnosis and treatment
  53. Cytosolic levels of TFF1/pS2 in breast cancer: their relationship with clinical–pathological parameters and their prognostic significance
  54. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
  55. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
  56. Can additional immunohistochemistry staining replace the surgical excision for the diagnosis of papillary breast lesions classified as benign on 14-gage core needle biopsy?
  57. Risk-Reducing Mastectomy: Who Is a Candidate and What Are the Outcomes?
  58. Long-term quality of life after breast cancer: a French registry-based controlled study
  59. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis
  60. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
  61. Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients
  62. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells
  63. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells
  64. MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case–control study
  65. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
  66. Pure mucinous carcinoma with axillary lymph node metastasis in a male breast
  67. Simplifying clinical use of the genetic risk prediction model BRCAPRO
  68. Synchronous benign-appearing calcifications in patients with ductal carcinoma in situ may not be benign
  69. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects
  70. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1 , and BLM germ-line mutations
  71. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer
  72. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression
  73. One-day core needle biopsy in a breast clinic: 4 years experience
  74. Preoperative breast MRI in early-stage breast cancer
  75. Techniques and Outcomes of Nipple Sparing Mastectomy in the Surgical Management of Breast Cancer
  76. Population-based survival-cure analysis of ER-negative breast cancer
  77. Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer
  78. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
  79. Poly(ADP-Ribose) Inhibition: Exploring a New Approach to Breast Cancer Prevention in BRCA1/2 Mutation Carriers
  80. Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial
  81. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast
  82. The association of reproductive factors and breastfeeding with long term survival from breast cancer
  83. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer
  84. Non-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy
  85. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer
  86. Genetic variants in trinucleotide repeat-containing 9 ( TNRC9 ) are associated with risk of estrogen receptor positive breast cancer in a Chinese population
  87. Breast cancer in young women
  88. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
  89. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
  90. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research
  91. Plasma S100P level as a novel prognostic marker of metastatic breast cancer
  92. A Study on the Association of Cytochrome-P450 1A1 Polymorphism and Breast Cancer Risk in North Indian Women
  93. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer
  94. Evaluating the organization and delivery of breast cancer services: use of performance measures to identify knowledge gaps
  95. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy
  96. Acknowledgement of reviewers 2015
  97. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial
  98. Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan
  99. Toxicity of (neo)adjuvant chemotherapy for BRCA1 - and BRCA2 -associated breast cancer
  100. Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients
  101. Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis
  102. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
  103. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients
  104. Mammary field cancerization: molecular evidence and clinical importance
  105. Preoperative CT evaluation of intraductal spread of breast cancer and surgical treatment
  106. Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy
  107. The impact of diabetes on survival following breast cancer
Search Result: